NCT01777308View on ClinicalTrials.gov

Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination

PHASE3CompletedINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

May 3, 2013

Primary Completion Date

July 3, 2014

Study Completion Date

April 20, 2016

Conditions
Infections, Meningococcal
Interventions
BIOLOGICAL

Meningococcal conjugate vaccine GSK134612

Single dose to be administrated intramuscularly in the deltoid of the non-dominant arm

Trial Locations (8)

2031

GSK Investigational Site, Randwick

2145

GSK Investigational Site, Westmead

2606

GSK Investigational Site, Garran

3053

GSK Investigational Site, Carlton

4029

GSK Investigational Site, Herston

4075

GSK Investigational Site, Sherwood

5006

GSK Investigational Site, North Adelaide

6008

GSK Investigational Site, Subiaco

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01777308 - Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination | Biotech Hunter | Biotech Hunter